Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management
- R. Vuppalanchi, N. Chalasani
- MedicineHepatology
- 1 January 2009
Health care providers should not only focus on liver disease but also concentrate on aggressively modifying and treating their cardiovascular risk factors.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Z. Younossi, V. Ratziu, M. Zuin
- MedicineThe Lancet
- 5 December 2019
Dyslipidemia in patients with nonalcoholic fatty liver disease.
- H. Chatrath, R. Vuppalanchi, N. Chalasani
- Medicine, BiologySeminars in liver disease (Print)
- 1 February 2012
Omega-3 fatty acids are perhaps the first choice to treat hypertriglyceridemia because of their safety, tolerability, and efficacy in improving serum triglycerides, as well as their potential to improve liver disease.
Liver injury from herbals and dietary supplements in the U.S. Drug‐Induced Liver Injury Network
- V. Navarro, H. Barnhart, R. Vuppalanchi
- MedicineHepatology
- 1 October 2014
Liver injury from nonbodybuilding H DS is more severe than from bodybuilding HDS or medications, as evidenced by differences in unfavorable outcomes (death and transplantation).
Vibration‐Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
- M. Siddiqui, R. Vuppalanchi, A. Sanyal
- MedicineClinical Gastroenterology and Hepatology
- 1 January 2019
Faecal microbiota transplantation plus selected use of vancomycin for severe‐complicated Clostridium difficile infection: description of a protocol with high success rate
- M. Fischer, B. Sipe, D. Rex
- Medicine, BiologyAlimentary Pharmacology and Therapeutics
- 1 August 2015
Severe and severe/complicated Clostridium difficile infection (CDI) can result in ICU admission, sepsis, toxic megacolon and death. In this setting, colectomy is the standard of care but it is…
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease
- L. N. Bell, J. Theodorakis, N. Chalasani
- Biology, MedicineHepatology
- 1 January 2010
This proteomic analysis reveals important information regarding the pathogenesis/progression of NAFLD and NASH and demonstrates key changes in serum protein expression levels between control subjects and patients with different stages of fatty liver.
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.
- K. Berman, S. Tandra, N. Chalasani
- MedicineClinical Gastroenterology and Hepatology
- 1 March 2011
Most Individuals With Advanced Cirrhosis Have Sleep Disturbances, Which Are Associated With Poor Quality of Life
- M. Ghabril, Mollie Jackson, N. Chalasani
- Medicine, PsychologyClinical Gastroenterology and Hepatology
- 1 August 2017
Therapeutic pipeline in nonalcoholic steatohepatitis
- R. Vuppalanchi, M. Noureddin, N. Alkhouri, A. Sanyal
- Medicine, BiologyNature reviews: Gastroenterology & hepatology
- 10 February 2021
NASH therapies that have progressed to phase II and beyond are summarized and some of the potential clinical challenges with the use of these new therapies when approved are discussed.
...
...